quavonlimab
mAbexperimental
Clinical trial activity
6 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
6
Phase 3
2
Phase 4
0
Earliest trial started Mar 16, 2021 (NCT04740307)
Timeline
Indications
Mechanism of action
- Cytotoxic T-lymphocyte protein 4ANTAGONIST
CTLA4
- Cytotoxic T-lymphocyte protein 4INHIBITOR
Cytotoxic T-lymphocyte protein 4 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4650419 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05899049 | Phase 3 | Jul 27, 2022 | Eisai, Merck |
| NCT04938817 | Phase 1/Phase 2 (Phase 2) | Aug 19, 2021 | Merck |
| NCT04895722 | Phase 2 | Jun 25, 2021 | Merck |
| NCT04700072 | Phase 1/Phase 2 (Phase 2) | May 3, 2021 | Merck |
| NCT04736706 | Phase 3 | Apr 14, 2021 | Eisai, Merck |
| NCT04740307 | Phase 2 | Mar 16, 2021 | Merck |
Showing 6 of 6 trials
Page 1 / 1